Oligomerix Relocates Corporate Headquarters To Valhalla, New York
01/14/2014
The new facilities will advance compounds in development and provide expanded space for a growing management and clinical team, the company said.
Oligomerix, which is focused on the development of small molecule drugs aimed specifically at inhibiting tau aggregation at the earliest steps of tau self-association into toxic oligomers in neurons, has continued to successfully advance its research, resulting in the need to add staff and expand its office and lab space.
"We're extremely encouraged by the preclinical data we've observed in our lead small molecule program, and are eager to continue our research in this space," stated James Moe, Ph.D., MBA, President and CEO of Oligomerix. "As New York Medical College is already providing space for in vivo mouse studies for our lead compound, we believe the decision to move and expand Oligomerix's corporate headquarters will benefit the company's logistical needs."
Oligomerix recently announced the appointment of James Hendrix, Ph.D., as the company's Senior Director of Chemistry, and plans to potentially recruit up to five employees in 2014.
Article Discussion
Most Read
- The Comeback Kid: Textiles Are Returning Stateside
- Artificial Intelligence in Supply Chain Management
- 2018 Top States for Doing Business: Georgia Ranks #1 Fifth Year in a Row
- 32nd Annual Corporate Survey & the 14th Annual Consultants Survey
- Front Line: Construction Industry Faces a Labor Shortage
- Four Key Concepts to Maximize Incentives
- What Is the Future of Work?
SPECIAL PRESENTATIONS
-
2018 Top States for Doing Business: Georgia Ranks #1 Fifth Year in a Row
-
2018 Leading Metro Locations: Pacific and Mountain Metros Dominate the List
-
2018 Gold & Silver Shovel Awards Recognize States’ Efforts to Attract High-Value Investment & Large Job-Creating Projects
-
32nd Annual Corporate Survey & the 14th Annual Consultants Survey